Anti‐angiogenic therapies for gastric cancer

Abstract

Tumor angiogenesis plays an important role in cancer cell proliferation and metastasis. In gastric cancer, among the numerous clinical trials investigating various anti-angiogenic therapies, such as antivascular endothelial growth factor (VEGF) or anti-VEGF receptor (VEGFR)-2 monoclonal antibodies, VEGF-Trap and VEGFR tyrosine kinase inhibitors, the anti-VEGFR-2 antibody ramucirumab was shown to prolong overall survival not only as a single agent but also in combination with paclitaxel as a second-line chemotherapy. Additionally, apatinib, a selective VEGFR-2 tyrosine kinase inhibitor, prolonged survival as a third-line or later treatment option in patients with advanced gastric cancer. Preliminary results of studies investigating ramucirumab plus immune checkpoint inhibitors in gastric cancer were encouraging, and further investigations are ongoing. In China, apatinib in combination with cytotoxic agents is being investigated for systemic chemotherapy or maintenance therapy as an earlier treatment option. The clinical activity in gastric cancer of the multikinase inhibitor regorafenib was suggested in a randomized phase II study.A global phase III trial comparing regorafenib with placebo is currently ongoing. Further studies of anti-angiogenic therapy combined with not only chemotherapy but also immune checkpoint inhibitors are also being pursued, providing hope for improved survival in patients with gastric cancer. K E Y W O R D Santi-angiogenic therapy, gastric cancer, immune therapy 208

m6A RNA Methylation Regulators Contribute to Malignant Progression and Have Clinical Prognostic Impact in Gastric Cancer

“…Surgery is the first choice for the treatment of gastric cancer, combined with adjuvant chemotherapy, radiotherapy, targeted drugs, and immunotherapy (28). Although, the global incidence of gastric cancer has declined significantly over the past few decades, the 5-year survival rate of gastric cancer is usually <30%, and there are still many key issues that remain unresolved (29). The occurrence and development of gastric cancer is very complicated.…”

Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy

“…VEGF is the most typical activator of angiogenesis. Currently, anti-angiogenesis therapy is divided into three types (Cortez et al, 2018;Hironaka, 2019): (1) inhibiting VEGF; (2) inhibiting its receptor, VEGFR; and (3) inhibiting Angs ( Table 1).…”

The Extracellular Matrix: An Accomplice in Gastric Cancer Development and Progression

“…Accordingly, Ramucirumab is now used to treat gastric cancer patients with advanced or metastatic disease on or after first-line chemotherapy [191]. Currently, there are also a number of clinical trials addressing the inclusion of Apatinib, a highly selective VEGFR2 inhibitor, in gastric cancer treatment regimens, including phase III and IV trials [191,194].…”